A unique range of over 3000 novel substituted fluoro aromatic compounds functionalised with a variety of synthetically useful reactive groups.
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ.
Read More >
Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >